MOULDER LEON O JR 4
4 · Zenas BioPharma, Inc. · Filed May 18, 2026
Research Summary
AI-generated summary of this filing
Zenas BioPharma (ZBIO) CEO Leon Moulder Buys 60,000 Shares
What Happened
Leon O. Moulder Jr., the company's chief executive officer and chairman, purchased 60,000 shares of Zenas BioPharma (ZBIO) in open‑market transactions on May 18, 2026. The weighted average price reported was $16.88 per share, for a total transaction value of $1,012,800. This was an outright purchase (ticker code P), which is a direct buy rather than a sale or option exercise.
Key Details
- Transaction date: 2026-05-18 (filed the same day). Filing appears timely.
- Price: weighted average $16.88; individual trades ranged from $16.59 to $16.97 (footnote F1).
- Shares acquired: 60,000; total value ≈ $1,012,800.
- Shares owned after transaction: not disclosed in this Form 4.
- Footnotes of note:
- F1: Weighted average; reporting person will provide breakdown of shares at each price on request.
- F2: Moulder is Trustee of the Leon O. Moulder, Jr. Revocable Trust and may have voting/dispositive power over shares held by the Trust; he disclaims beneficial ownership except to the extent of pecuniary interest.
- F3: He is also Managing Member of Tellus BioVentures LLC, which may hold shares; he disclaims beneficial ownership except as to pecuniary interest.
Context
Open‑market purchases by executives can be interpreted by retail investors as a direct personal investment in the company, but filings are factual records and do not explain motivation. This was a purchase (not an option exercise, gift, or sale) executed across multiple trades at slightly varying prices.
Insider Transaction Report
- Purchase
Common Stock
[F1][F2]2026-05-18$16.88/sh+60,000$1,012,800→ 96,928 total(indirect: See Footnote)
- 1,786,039(indirect: See Footnote)
Common Stock
[F3] - 423,155
Common Stock
Footnotes (3)
- [F1]The price reported is a weighted average price. These shares were purchased in multiple transactions ranging from $16.59 to $16.97, inclusive. The Reporting Person undertakes to provide the Issuer, any security holder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares purchased at each separate price within the range.
- [F2]The reporting person is a Trustee of the Leon O. Moulder, Jr. Revocable Trust U/A dtd 9/9/2008 (the "Trust") and may be deemed to have voting and dispositive power over the shares held by the Trust. The reporting person is the Issuer's chief executive officer and Chairman of its board of directors. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.
- [F3]Leon O. Moulder, Jr. is the Managing Member of Tellus BioVentures LLC ("Tellus") and may be deemed to have sole voting and dispositive power over the shares held by Tellus. Mr. Moulder is the Issuer's chief executive officer and Chairman of its board of directors. The reporting person disclaims beneficial ownership of such securities except to the extent of his pecuniary interest therein.